QT
EGRX

Quantamental Technologies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Quantamental Technologies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,777
Closed -$101K – 1419
2019
Q3 		$101K Sell
1,777
-522
-23% -$29.4K 0.03% 742
2019
Q2 		$128K Buy
2,299
+743
+48% +$38.8K 0.05% 588
2019
Q1 		$79K Buy
+1,556
New +$69.2K 0.04% 691

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Quantamental Technologies's EGRX Position: Q4 2019 in Review

Quantamental Technologies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 1,777 shares — an estimated $101K sold.

Quantamental Technologies first reported a position in EGRX in Q1 2019 and held it in 3 quarters. The position peaked at $128K in Q2 2019. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

  • Quantamental Technologies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 1,777 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $101K.
  • Quantamental Technologies first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 3 quarters.
  • Quantamental Technologies's Eagle Pharmaceuticals, Inc. position peaked at $128K in Q2 2019.
  • 176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.